Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
CIPLA | GLENMARK PHARMA | CIPLA/ GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 37.1 | 15.2 | 245.0% | View Chart |
P/BV | x | 4.3 | 2.5 | 173.1% | View Chart |
Dividend Yield | % | 0.5 | 0.4 | 117.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
GLENMARK PHARMA Mar-19 |
CIPLA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 712 | 82.3% | |
Low | Rs | 357 | 484 | 73.8% | |
Sales per share (Unadj.) | Rs | 207.0 | 349.6 | 59.2% | |
Earnings per share (Unadj.) | Rs | 18.6 | 32.8 | 56.7% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 44.3 | 74.8% | |
Dividends per share (Unadj.) | Rs | 4.00 | 2.00 | 200.0% | |
Dividend yield (eoy) | % | 0.8 | 0.3 | 253.7% | |
Book value per share (Unadj.) | Rs | 195.5 | 198.6 | 98.4% | |
Shares outstanding (eoy) | m | 806.35 | 282.17 | 285.8% | |
Bonus/Rights/Conversions | ESOS | - | - | ||
Price / Sales ratio | x | 2.3 | 1.7 | 133.1% | |
Avg P/E ratio | x | 25.3 | 18.2 | 139.0% | |
P/CF ratio (eoy) | x | 14.2 | 13.5 | 105.4% | |
Price / Book Value ratio | x | 2.4 | 3.0 | 80.1% | |
Dividend payout | % | 21.5 | 6.1 | 352.6% | |
Avg Mkt Cap | Rs m | 379,912 | 168,625 | 225.3% | |
No. of employees | `000 | 25.8 | 12.0 | 214.7% | |
Total wages/salary | Rs m | 30,270 | 20,561 | 147.2% | |
Avg. sales/employee | Rs Th | 6,459.6 | 8,196.0 | 78.8% | |
Avg. wages/employee | Rs Th | 1,171.2 | 1,708.1 | 68.6% | |
Avg. net profit/employee | Rs Th | 580.2 | 768.5 | 75.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 98,655 | 169.2% | |
Other income | Rs m | 3,442 | 2,081 | 165.4% | |
Total revenues | Rs m | 170,391 | 100,736 | 169.1% | |
Gross profit | Rs m | 32,060 | 15,858 | 202.2% | |
Depreciation | Rs m | 11,747 | 3,259 | 360.4% | |
Interest | Rs m | 1,974 | 3,346 | 59.0% | |
Profit before tax | Rs m | 21,782 | 11,335 | 192.2% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
Tax | Rs m | 6,312 | 3,756 | 168.0% | |
Profit after tax | Rs m | 14,995 | 9,250 | 162.1% | |
Gross profit margin | % | 19.2 | 16.1 | 119.5% | |
Effective tax rate | % | 29.0 | 33.1 | 87.4% | |
Net profit margin | % | 9.0 | 9.4 | 95.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 66,968 | 174.8% | |
Current liabilities | Rs m | 43,931 | 40,211 | 109.3% | |
Net working cap to sales | % | 43.8 | 27.1 | 161.5% | |
Current ratio | x | 2.7 | 1.7 | 160.0% | |
Inventory Days | Days | 96 | 83 | 114.9% | |
Debtors Days | Days | 85 | 81 | 104.8% | |
Net fixed assets | Rs m | 107,424 | 33,322 | 322.4% | |
Share capital | Rs m | 1,613 | 282 | 571.4% | |
"Free" reserves | Rs m | 156,018 | 55,770 | 279.8% | |
Net worth | Rs m | 157,630 | 56,052 | 281.2% | |
Long term debt | Rs m | 23,693 | 35,738 | 66.3% | |
Total assets | Rs m | 236,626 | 132,888 | 178.1% | |
Interest coverage | x | 12.0 | 4.4 | 274.3% | |
Debt to equity ratio | x | 0.2 | 0.6 | 23.6% | |
Sales to assets ratio | x | 0.7 | 0.7 | 95.0% | |
Return on assets | % | 7.2 | 9.5 | 75.7% | |
Return on equity | % | 9.5 | 16.5 | 57.6% | |
Return on capital | % | 12.8 | 17.8 | 72.1% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 62,998 | 88.9% | |
Fx outflow | Rs m | 6,764 | 22,859 | 29.6% | |
Net fx | Rs m | 49,272 | 40,140 | 122.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 13,242 | 231.7% | |
From Investments | Rs m | 1,040 | -6,990 | -14.9% | |
From Financial Activity | Rs m | -29,488 | -7,387 | 399.2% | |
Net Cashflow | Rs m | 2,340 | -2,971 | -78.8% |
Indian Promoters | % | 16.0 | 48.3 | 33.1% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 6.9 | 176.8% | |
FIIs | % | 23.7 | 34.4 | 68.9% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 10.5 | 249.5% | |
Shareholders | 161,166 | 56,727 | 284.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: WYETH PFIZER ALKEM LABORATORIES SHASUN PHARMA SANOFI INDIA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More